Avacta Group Plc (AVCTF)
USD 0.59
(0.0%)
USD 0.59
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 34.29 Million GBP | -2.2% |
| 2022 | 35.06 Million GBP | 12.74% |
| 2021 | 31.1 Million GBP | 44.54% |
| 2020 | 21.51 Million GBP | 49.41% |
| 2019 | 14.4 Million GBP | 17.07% |
| 2018 | 12.3 Million GBP | 25.84% |
| 2017 | 9.77 Million GBP | 40.97% |
| 2016 | 6.93 Million GBP | 1.17% |
| 2015 | 6.85 Million GBP | 66.93% |
| 2014 | 4.1 Million GBP | 21.26% |
| 2013 | 3.38 Million GBP | 7.39% |
| 2012 | 3.15 Million GBP | -12.66% |
| 2011 | 3.61 Million GBP | -3.11% |
| 2010 | 3.72 Million GBP | 28.66% |
| 2009 | 2.89 Million GBP | 36.71% |
| 2008 | 2.11 Million GBP | 51.42% |
| 2007 | 1.39 Million GBP | 921.17% |
| 2006 | 137 Thousand GBP | -55.52% |
| 2005 | 308 Thousand GBP | -14.92% |
| 2004 | 362 Thousand GBP | 262.0% |
| 2003 | 100 Thousand GBP | -39.02% |
| 2002 | 164 Thousand GBP | 5.13% |
| 2001 | 156 Thousand GBP | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 6.38 Million GBP | -62.04% |
| 2023 Q2 | 16.2 Million GBP | 153.94% |
| 2023 FY | 34.29 Million GBP | -2.2% |
| 2023 Q4 | 18.08 Million GBP | 224.25% |
| 2023 Q3 | 5.57 Million GBP | -65.59% |
| 2022 Q2 | 12.94 Million GBP | 73.6% |
| 2022 Q3 | 15.35 Million GBP | 18.61% |
| 2022 FY | 35.06 Million GBP | 12.74% |
| 2022 Q1 | 7.45 Million GBP | -49.65% |
| 2022 Q4 | 16.81 Million GBP | 9.48% |
| 2021 Q3 | 8.12 Million GBP | -30.95% |
| 2021 Q2 | 11.76 Million GBP | 98.01% |
| 2021 Q4 | 14.81 Million GBP | 82.31% |
| 2021 Q1 | 5.94 Million GBP | -47.05% |
| 2021 FY | 31.1 Million GBP | 44.54% |
| 2020 Q4 | 11.22 Million GBP | 62.63% |
| 2020 Q1 | 4.33 Million GBP | 0.0% |
| 2020 Q2 | 8.13 Million GBP | 87.86% |
| 2020 FY | 21.51 Million GBP | 49.41% |
| 2020 Q3 | 6.9 Million GBP | -15.21% |
| 2019 Q2 | 3.93 Million GBP | 0.0% |
| 2019 FY | 14.4 Million GBP | 17.07% |
| 2019 Q1 | 3.93 Million GBP | -28.24% |
| 2018 Q1 | 2.91 Million GBP | 6.42% |
| 2018 FY | 12.3 Million GBP | 25.84% |
| 2018 Q4 | 5.48 Million GBP | 0.0% |
| 2018 Q2 | 4.72 Million GBP | 62.07% |
| 2017 Q2 | 2.5 Million GBP | 0.0% |
| 2017 Q4 | 2.74 Million GBP | 0.0% |
| 2017 FY | 9.77 Million GBP | 40.97% |
| 2017 Q1 | 2.5 Million GBP | 4.84% |
| 2017 Q3 | 2.74 Million GBP | 9.53% |
| 2016 Q2 | 2.14 Million GBP | 0.0% |
| 2016 FY | 6.93 Million GBP | 1.17% |
| 2016 Q3 | 2.38 Million GBP | 11.5% |
| 2016 Q4 | 2.38 Million GBP | 0.0% |
| 2016 Q1 | 2.14 Million GBP | 61.27% |
| 2015 Q4 | 1.32 Million GBP | 0.0% |
| 2015 FY | 6.85 Million GBP | 66.93% |
| 2015 Q3 | 1.32 Million GBP | -44.52% |
| 2015 Q2 | 2.39 Million GBP | 0.0% |
| 2015 Q1 | 2.39 Million GBP | 131.11% |
| 2014 Q2 | 1 Million GBP | 0.0% |
| 2014 Q1 | 1 Million GBP | 78.51% |
| 2014 Q4 | 1.03 Million GBP | 0.0% |
| 2014 FY | 4.1 Million GBP | 21.26% |
| 2014 Q3 | 1.03 Million GBP | 2.99% |
| 2013 FY | 3.38 Million GBP | 7.39% |
| 2013 Q2 | 886.5 Thousand GBP | 0.0% |
| 2013 Q3 | 563 Thousand GBP | -36.49% |
| 2013 Q4 | 563 Thousand GBP | 0.0% |
| 2013 Q1 | 886.5 Thousand GBP | 9.92% |
| 2012 Q4 | 806.5 Thousand GBP | 0.0% |
| 2012 FY | 3.15 Million GBP | -12.66% |
| 2012 Q3 | 806.5 Thousand GBP | 0.0% |
| 2011 FY | 3.61 Million GBP | -3.11% |
| 2010 FY | 3.72 Million GBP | 28.66% |
| 2009 FY | 2.89 Million GBP | 36.71% |
| 2008 FY | 2.11 Million GBP | 51.42% |
| 2007 FY | 1.39 Million GBP | 921.17% |
| 2006 FY | 137 Thousand GBP | -55.52% |
| 2005 FY | 308 Thousand GBP | -14.92% |
| 2004 FY | 362 Thousand GBP | 262.0% |
| 2003 FY | 100 Thousand GBP | -39.02% |
| 2002 FY | 164 Thousand GBP | 5.13% |
| 2001 FY | 156 Thousand GBP | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -2218.847% |
| CSL Limited | 3.44 Billion USD | 99.006% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 60.489% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -597.247% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -13001.488% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -16.029% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 7.96% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -2183.11% |
| Mesoblast Limited | 5.9 Million USD | -480.989% |
| Marizyme, Inc. | 19.23 Million USD | -78.224% |
| Genus plc | 147.7 Million USD | 76.784% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -290.581% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2456.008% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -311.2% |
| ContraFect Corporation | 56.88 Million USD | 39.725% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -677.785% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 37.7 Million USD | 9.067% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -1128.875% |
| MultiCell Technologies, Inc. | 567.42 USD | -6043042.646% |
| Accustem Sciences Inc. | 3.74 Million USD | -815.274% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 60.102% |
| EV Biologics, Inc. | 531.96 Thousand USD | -6345.949% |
| Q BioMed Inc. | 3.43 Million USD | -897.78% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -38.742% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -1205.032% |
| Biomind Labs Inc. | 994.18 Thousand USD | -3349.067% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -410.419% |
| Skye Bioscience, Inc. | 13.54 Million USD | -153.108% |
| SQZ Biotechnologies Company | 85.61 Million USD | 59.95% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 137260.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -580.081% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -1075.831% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -114.175% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -8702.103% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 84.793% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1573.74% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1768.568% |
| GB Sciences, Inc. | 1.42 Million USD | -2313.923% |
| Alpha Cognition Inc. | 9.7 Million USD | -253.301% |
| argenx SE | 1.53 Billion USD | 97.764% |
| HST Global, Inc. | 140.9 Thousand USD | -24235.2% |
| Halberd Corporation | 74.84 Thousand USD | -45716.52% |
| Enzolytics Inc. | 2.17 Million USD | -1473.292% |
| Resverlogix Corp. | 12.71 Million USD | -169.745% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -839.27% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 40.303% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 65.479% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -3184.483% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1848.652% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -1325.819% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -1739.227% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -2071.139% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -907.055% |
| AVAX Technologies, Inc. | 7.31 Million USD | -369.067% |
| ONE Bio Corp. | 6.44 Million USD | -432.132% |
| Zenith Capital Corp. | 8.94 Million USD | -283.428% |
| Genscript Biotech Corporation | 825.34 Million USD | 95.845% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -196731.41% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -1296.561% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -19893.12% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -1685.095% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -2948.244% |
| Agentix Corp. | 1.37 Million USD | -2399.716% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 2.41 Million USD | -1322.755% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1638.814% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -215.542% |
| BioStem Technologies, Inc. | 22.97 Million USD | -49.25% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -18794.123% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -2467.71% |
| LadRx Corporation | 3.81 Million USD | -799.577% |
| Cell Source, Inc. | 4.32 Million USD | -692.769% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -8153.125% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3613.008% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3613.008% |
| NovAccess Global Inc. | 2.46 Million USD | -1290.082% |
| Affymax, Inc. | 39.38 Million USD | 12.939% |
| Itoco Inc. | 919.14 Thousand USD | -3630.649% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -709.029% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -2964.343% |
| CytoDyn Inc. | 18.05 Million USD | -89.888% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -136139.024% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -15480.84% |
| Qrons Inc. | 643.67 Thousand USD | -5227.206% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -2315.142% |
| SYBLEU INC | 160.87 Thousand USD | -21214.553% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -1437.752% |
| Rebus Holdings, Inc. | 664 Thousand USD | -5064.157% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1787.883% |
| Mobile Lads Corp. | 554.54 Thousand USD | -6083.437% |
| International Stem Cell Corporation | 5.27 Million USD | -550.541% |
| Bioxytran, Inc. | 3.82 Million USD | -797.609% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -65038.103% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -168459.21% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 5.449% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -2019.283% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -4560.012% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -1002.218% |
| Neutra Corp. | 243.82 Thousand USD | -13963.596% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -96.426% |
| PureTech Health plc | 144.59 Million USD | 76.286% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -67.351% |
| IXICO plc | 4.7 Million USD | -628.489% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -289.792% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 70.878% |
| CSL Limited | 3.89 Billion USD | 99.119% |
| Cellectis S.A. | 97.32 Million USD | 64.766% |